Automate Your Wheel Strategy on BFRIW
With Tiblio's Option Bot, you can configure your own wheel strategy including BFRIW - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BFRIW
- Rev/Share 4.1898
- Book/Share -0.4992
- PB -1.6323
- Debt/Equity -1.072
- CurrentRatio 0.9557
- ROIC -12.169
- MktCap 8692612.0
- FreeCF/Share -0.999
- PFCF -0.9305
- PE -0.4592
- Debt/Assets 0.2484
- DivYield 0
- ROE -11.5142
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
About Biofrontera Inc. (BFRIW)
- IPO Date 2021-10-29
- Website https://www.biofrontera-us.com
- Industry Drug Manufacturers - Specialty & Generic
- CEO Hermann Luebbert
- Employees 92
Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.